SG48234A1 - Use of sertindole for the treatment of schizophrenia - Google Patents

Use of sertindole for the treatment of schizophrenia

Info

Publication number: SG48234A1
Authority: SG; Singapore
Prior art keywords: sertindole; schizophrenia; treatment; dopamine neurones; neurones
Prior art date: 1989-04-11

Application number

SG1996008153A

Other languages

English (en)

Inventor

Jens Kristian Perregaard

Torben Skarsfeldt

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-04-11

Filing date

1990-03-30

Publication date

1998-04-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10654774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG48234(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-03-30 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

1998-04-17 Publication of SG48234A1 publication Critical patent/SG48234A1/en

Links

201000000980 schizophrenia Diseases 0.000 title 1
GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 title 1
229960000652 sertindole Drugs 0.000 title 1
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 4
229960003638 dopamine Drugs 0.000 abstract 2
210000002569 neuron Anatomy 0.000 abstract 2
241001573498 Compacta Species 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
210000003523 substantia nigra Anatomy 0.000 abstract 1
210000004515 ventral tegmental area Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Saccharide Compounds (AREA)

SG1996008153A 1989-04-11 1990-03-30 Use of sertindole for the treatment of schizophrenia SG48234A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898908085A GB8908085D0 (en)	1989-04-11	1989-04-11	New therapeutic use

Publications (1)

Publication Number	Publication Date
SG48234A1 true SG48234A1 (en)	1998-04-17

Family

ID=10654774

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG1996008153A SG48234A1 (en)	1989-04-11	1990-03-30	Use of sertindole for the treatment of schizophrenia

Country Status (18)

Country	Link
US (1)	US5112838A (fr)
EP (1)	EP0392959B1 (fr)
JP (1)	JP2775191B2 (fr)
KR (1)	KR920008703B1 (fr)
AT (1)	ATE157005T1 (fr)
AU (1)	AU621735B2 (fr)
CA (1)	CA2014208C (fr)
CY (1)	CY2082B1 (fr)
DE (2)	DE69031290T2 (fr)
DK (1)	DK0392959T3 (fr)
GB (1)	GB8908085D0 (fr)
HK (1)	HK1002825A1 (fr)
IE (1)	IE81157B1 (fr)
IL (1)	IL94021A (fr)
NL (1)	NL980008I1 (fr)
NZ (2)	NZ243765A (fr)
SG (1)	SG48234A1 (fr)
ZA (1)	ZA902785B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5238945A (en) *	1989-04-11	1993-08-24	H. Lundbeck A/S	Method of treating psychoses
DK238190D0 (da) *	1990-10-03	1990-10-03	Lundbeck & Co As H	Depotderivater
US5643784A (en) *	1990-12-04	1997-07-01	H, Lundbeck A/S	Indan derivatives
NZ243065A (en) *	1991-06-13	1995-07-26	Lundbeck & Co As H	Piperidine derivatives and pharmaceutical compositions
DK206591D0 (da) *	1991-12-23	1991-12-23	Lundbeck & Co As H	Behandling af psykoser
DK8492D0 (da) *	1992-01-23	1992-01-23	Lundbeck & Co As H	Behandling af psykoser
DK123493D0 (da) *	1993-11-01	1993-11-01	Lundbeck & Co As H	Compounds
WO1997035584A1 (fr) *	1996-03-25	1997-10-02	Eli Lilly And Company	Procede de traitement de la douleur
ZA973433B (en) *	1996-04-24	1997-12-10	Shionogi & Co	A sertindole-containing preparation and a method for producing the same.
CA2306817A1 (fr) *	1997-10-27	1999-05-06	Cortex Pharmaceuticals Inc.	Traitement de la schizophrenie par ampakines et neuroleptiques
GB9805716D0 (en) *	1998-03-17	1998-05-13	Merck Sharp & Dohme	Therapeutic agents
US6489341B1 (en)	1999-06-02	2002-12-03	Sepracor Inc.	Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
FR2802101B1 (fr)	1999-12-10	2003-02-28	Aventis Pharma Sa	Association de cymemazine et d'un neuroleptique atypique
US20040023951A1 (en) *	2001-06-18	2004-02-05	Bymaster Franklin Porter	Combination therapy for treatment of psychoses
ATE503845T1 (de) *	2001-12-10	2011-04-15	Novartis Pharma Gmbh	Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
US20050101788A1 (en) *	2002-03-27	2005-05-12	Jacopo Zanon	Method for manufacture of sertindole
EP1633400A2 (fr) *	2003-05-16	2006-03-15	Pfizer Products Inc.	Combinaisons therapeutiques d'antipsychotiques atypiques avec des modulateurs de l'acide 4-aminobutanoique et/ou des medicaments anticonvulsivants
GB0326148D0 (en)	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
CA2567249A1 (fr) *	2004-04-19	2006-10-05	Jds Pharmaceuticals, Llc	Combinaisons de lithium et utilisations associees
EP1753460A2 (fr) *	2004-05-11	2007-02-21	Pfizer Products Inc.	Combinaison d'antipsychotiques atypiques et d'antagonistes du recepteur de 5-ht1b
TW200612905A (en) *	2004-06-16	2006-05-01	Janssen Pharmaceutica Nv	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) *	2004-06-16	2013-01-31	Janssen Pharmaceutica Nv	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200616608A (en) *	2004-07-09	2006-06-01	Forest Laboratories	Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
PE20060500A1 (es) *	2004-08-24	2006-07-13	Janssen Pharmaceutica Nv	Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
BRPI0610864A2 (pt) *	2005-05-20	2010-08-03	Janssen Pharmaceutica Nv	processo para preparação de derivados de sulfamida
US20070212412A1 (en) *	2005-09-08	2007-09-13	H. Lundbeck A/S	Stable solid formulation of sertindole
US8937096B2 (en)	2005-12-19	2015-01-20	Janssen Pharmaceutica Nv	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en)	2005-12-19	2014-05-06	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155823A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
AR058389A1 (es) *	2005-12-19	2008-01-30	Janssen Pharmaceutica Nv	Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070155827A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) *	2005-12-19	2013-07-30	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155824A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8691867B2 (en) *	2005-12-19	2014-04-08	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191450A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191474A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191460A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191451A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
JP2009537635A (ja) *	2006-05-19	2009-10-29	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	癲癇の処置のための共同−療法
TW200821296A (en) *	2006-06-01	2008-05-16	Lundbeck & Co As H	Use of sertindole for the preventive treatment of suicidal behaviour
EP2041304B1 (fr)	2006-06-12	2011-09-07	Hadasit Medical Research Services & Development Limited	Génotypes rgs2 associés aux symptômes extrapyramidaux induits par un médicament antipsychotique
PL2083811T3 (pl)	2006-11-22	2017-05-31	Clinical Research Associates, Llc	Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
WO2008106144A2 (fr) *	2007-02-28	2008-09-04	Nupathe Inc.	Implants destinés au traitement d'états psychiatriques
US20090247617A1 (en) *	2008-03-26	2009-10-01	Abdel-Magid Ahmed F	Process for the preparation of benzo-fused heteroaryl sulfamates
US20110034565A1 (en)	2008-04-18	2011-02-10	University College Dublin, National University Of Ireland, Dublin	Psycho-pharmaceuticals
PE20110060A1 (es)	2008-06-23	2011-01-31	Janssen Pharmaceutica Nv	Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
EP2321011A1 (fr) *	2008-06-25	2011-05-18	Pfizer Inc.	Composés diaryle et leurs utilisations
US8815939B2 (en)	2008-07-22	2014-08-26	Janssen Pharmaceutica Nv	Substituted sulfamide derivatives
US8252801B1 (en)	2009-06-03	2012-08-28	Abbott Laboratories	Treatment of schizophrenia and related disorders
WO2014078568A1 (fr)	2012-11-14	2014-05-22	The Johns Hopkins University	Méthodes et compositions pour le traitement de la schizophrénie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4359468A (en) *	1981-02-25	1982-11-16	Boehringer Ingelheim Ltd.	Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones
IE58370B1 (en) *	1985-04-10	1993-09-08	Lundbeck & Co As H	Indole derivatives
US4742057A (en) *	1985-12-05	1988-05-03	Fujisawa Pharmaceutical Co., Ltd.	Antiallergic thiazole compounds
ZA891901B (en) *	1988-03-17	1989-11-29	Merrell Dow Pharma	Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy

1989
- 1989-04-11 GB GB898908085A patent/GB8908085D0/en active Pending
1990
- 1990-03-21 IE IE105190A patent/IE81157B1/en not_active IP Right Cessation
- 1990-03-30 DK DK90610022T patent/DK0392959T3/da active
- 1990-03-30 EP EP90610022A patent/EP0392959B1/fr not_active Expired - Lifetime
- 1990-03-30 AT AT90610022T patent/ATE157005T1/de active
- 1990-03-30 DE DE69031290T patent/DE69031290T2/de not_active Expired - Lifetime
- 1990-03-30 DE DE1998175011 patent/DE19875011I2/de active Active
- 1990-03-30 SG SG1996008153A patent/SG48234A1/en unknown
- 1990-04-03 NZ NZ243765A patent/NZ243765A/en unknown
- 1990-04-03 NZ NZ233179A patent/NZ233179A/en unknown
- 1990-04-05 IL IL9402190A patent/IL94021A/en active Protection Beyond IP Right Term
- 1990-04-06 JP JP2090502A patent/JP2775191B2/ja not_active Expired - Lifetime
- 1990-04-09 CA CA002014208A patent/CA2014208C/fr not_active Expired - Lifetime
- 1990-04-10 AU AU53037/90A patent/AU621735B2/en not_active Expired
- 1990-04-11 US US07/508,240 patent/US5112838A/en not_active Expired - Lifetime
- 1990-04-11 KR KR1019900004984A patent/KR920008703B1/ko not_active Expired
- 1990-04-11 ZA ZA902785A patent/ZA902785B/xx unknown
1998
- 1998-02-18 NL NL980008C patent/NL980008I1/nl unknown
- 1998-02-19 HK HK98101302A patent/HK1002825A1/en not_active IP Right Cessation
- 1998-10-16 CY CY9802082A patent/CY2082B1/xx unknown

Also Published As

Publication number	Publication date
NL980008I1 (nl)	1998-05-06
DK0392959T3 (da)	1999-03-29
NZ233179A (en)	1996-12-20
DE69031290D1 (de)	1997-09-25
AU5303790A (en)	1990-10-18
EP0392959B1 (fr)	1997-08-20
JPH02290872A (ja)	1990-11-30
NZ243765A (en)	1997-09-22
KR920008703B1 (ko)	1992-10-08
US5112838A (en)	1992-05-12
IE901051L (en)	1990-10-11
ATE157005T1 (de)	1997-09-15
KR900015730A (ko)	1990-11-10
GB8908085D0 (en)	1989-05-24
EP0392959A3 (fr)	1992-05-06
DE69031290T2 (de)	1998-01-02
CA2014208A1 (fr)	1990-10-11
EP0392959A2 (fr)	1990-10-17
CY2082B1 (en)	1998-10-16
AU621735B2 (en)	1992-03-19
IL94021A (en)	1994-01-25
IE81157B1 (en)	2000-05-03
HK1002825A1 (en)	1998-09-18
CA2014208C (fr)	1996-03-19
ZA902785B (en)	1991-06-26
DE19875011I2 (de)	2004-07-01
JP2775191B2 (ja)	1998-07-16
IL94021A0 (fr)	1991-01-31

Publication	Publication Date	Title
CY2082B1 (en)	1998-10-16	Use of sertindole for the treatment of schizophrenia
TR200000129T2 (tr)	2000-07-21	Yepyeni spiroazabisiklik heterosiklik bileşikler.
DE69225421D1 (de)	1998-06-18	Sumatriptan enthaltende Arzneimittel
DE69825292D1 (de)	2004-09-02	Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
SE8804629D0 (sv)	1988-12-22	New therapeutically active compounds
FI901357A0 (fi)	1990-03-19	Intraoralt medicingivarsystem.
NZ237309A (en)	1993-02-25	1-(2-(4-morpholino)ethyl)-3-(arylcarbonyl)-indole derivatives and pharmaceutical compositions
NO178338C (no)	1996-03-06	Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse samt mellomprodukt
ES2033879T3 (es)	1995-04-01	Derivados cetonicos como medicamentos para el tratamiento o prevencion del sindrome de abstinencia.
NO167204C (no)	1991-10-23	Analogifremgangsmaate for fremstilling av terapeutisk aktive diacylderivater av 4-(trialkylbenzyl)-piperazinylforbindelser.
NO178336C (no)	1996-03-06	Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse og mellomprodukter
NO167456C (no)	1991-11-06	Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse 7-(3-amino-1-pyrrolidinyl)-8-brom-1-syklopropyl-6-fluor-1,4-dihydro-4-okso-3-quinolinkarboksylsyre
AP9901474A0 (en)	1999-03-31	Pharmaceutical composition for treating viral diseases.
NO984651L (no)	1998-12-03	Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
EP0266559A3 (en)	1990-06-06	Therapeutic agent for the treatment of peptic ulcer disease
MY133438A (en)	2007-11-30	Morpholinobenzamide salts
CA2154485A1 (fr)	1994-08-04	Composition pharmaceutique renfermant la 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone et son emploi pour le traitement des troubles du snc
JO1653B1 (en)	1991-11-27	The current benzimidazole is a therapeutically active method for preparing it
ES2150400A6 (es)	2000-11-16	Una composicion para el tratamiento de desordenes ulcerosos del tracto gastrointestinal.
IT8919216A0 (it)	1989-01-27	Dispositivo per la cura chirurgica dell'astigmatismo.
NO882279D0 (no)	1988-05-25	Fremgangsmaate for fremstilling av terapeutisk aktive endo-bicyklo (2,2,1) heptyl-adenosin-derivater.